AstraZeneca Paying for Genetic Testing Services for UK Lung Cancer Patients Receiving Iressa
April 07, 2010
AstraZeneca Paying for Genetic Testing Services for UK Lung Cancer Patients Receiving Iressa
Ahead of a cost-effectiveness appraisal by UK's NICE, AstraZeneca is paying for EGFR mutation testing for non-small cell lung cancer patients to determine if they will benefit from treatment with Iressa. The genetic testing program is part of a patient access scheme the company has agreed to with the National Health Service to provide more granularity about the cost and value of the treatment.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Despite PGx Leads, Avastin Access Debate Not Focused on Personalized Medicine Strategies
August 25, 2010 / Pharmacogenomics Reporter - With New Hires to Pharma Business Development Team, Qiagen Prioritizes Rx/Dx Partnership Strategy
April 21, 2010 / Pharmacogenomics Reporter - UK's NICE Cites Lack of Response Markers for BMS' Yervoy as Factor in Negative Recommendation
October 19, 2011 / Pharmacogenomics Reporter - Cancer Research UK on Path to Building National Genetic Testing Service
February 16, 2011 / Pharmacogenomics Reporter - UK's NICE Backs Iressa Coverage at Fixed Price; NHS Pays for Genetic Testing
June 2, 2010 / Pharmacogenomics Reporter